M. Ciampelli et A. Lanzone, INSULIN AND POLYCYSTIC-OVARY-SYNDROME - A NEW LOOK AT AN OLD SUBJECT, Gynecological endocrinology, 12(4), 1998, pp. 277-292
In recent years the metabolic implications of polycystic ovary syndrom
e (PCOS) have received a great deal of attention; in fact 50% of women
with PCOS are obese and a similar percentage of subjects was found to
show exaggerated insulin secretion and reduced insulin-stimulated glu
cose uptake. The presence of these features in women with PCOS has pro
found clinical implications in terms of morbidity due to diabetes mell
itus, dyslipidemia, hypertension and cardiovascular disease. Moreover,
hyperinsulinemia has recently been proposed as a possible independent
risk factor for endometrial and breast cancer. In the light of these
considerations, the importance of metabolic screening in patients with
PCOS in order to improve their quality of life cannot be underestimat
ed. In this review we analyze all the clinical pathologies in which hy
perinsulinemia of PCOS could be involved. Furthermore, in order to cla
rify the possible mechanisms leaning to the insulin disorders of the s
yndrome, we review the available data about the insulin receptor abnor
malities, as well as those concerning the insulin resistance and the e
xaggerated insulin secretion. Finally, we examine the main therapeutic
strategies to ameliorate the insulinemic status of PCOS patients in o
rder to potentially be able to prevent the long-term consequences of t
his syndrome.